Biological
PfSPZ Challenge clinical trials
- studies test it
- 16
- open now
- 3
- in phase 3
- 0
- first study started
- 2010
Keep track of what changes. Save the PfSPZ Challenge studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2012 (4)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 4 |
| 2014 | 3 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 16
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 5
Sanaria Inc. (11) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Medicines for Malaria Venture (1) · University of Maryland, Baltimore (1) · University Hospital Tuebingen (1) · University of Oxford (1)
Often tested with
Tested in the same studies.
Malaria Vaccines (3) · Chloroquine diphosphate (1) · Pyrimethamine (1) · P218 (1) · Pyronaridine tetraphosphate, artesunate drug combination (1) · MVA me-trap (1) · CHAD63 (1) · Fanasil, pyrimethamine drug combination (1)
Studies
Open first, then newest update. How each study uses PfSPZ Challenge is read from its arms, and is right about nine times in ten.
Testing it · 16
- Malaria CVD 36000; Gates INV090205Not yet recruitingPhase 1University of Maryland, BaltimoreNCT07558122Written as PfSPZ Challenge (NF54)
- Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve AdultsRecruitingPhase 1Sanaria Inc.NCT06862453Written as PfSPZ Challenge (NF54)
- Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in AdultsNot yet recruitingPhase 1/2University Hospital TuebingenNCT05441410Written as PfSPZ Challenge (NF54)
- Controlled Human Malaria Infection Transmission Model - Phase ASuspendedPhase 1/2University of OxfordNCT04280692Written as PfSPZ Challenge
- Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...CompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03952650Written as PfSPZ Challenge
- Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge ModelCompletedPhase 1Medicines for Malaria VentureNCT03707041Written as PfSPZ Challenge
- Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian AdultsCompletedPhase 1Sanaria Inc.NCT03420053Written as PfSPZ Challenge
- Sequential Optimization of Dose and Schedule of PfSPZ VaccineCompletedPhase 1Sanaria Inc.NCT02704533Written as PfSPZ Challenge (NF54)
- Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine ProphylaxisCompletedPhase 1Sanaria Inc.NCT01728701Written as PfSPZ Challenge
- Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under ChemoprophylaxisCompletedPhase 1Sanaria Inc.NCT02115516Written as PfSPZ Challenge
- Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian AdultsCompletedPhase 1Sanaria Inc.NCT02132299Written as PfSPZ Challenge
- Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune AdultsCompletedPhase 1Sanaria Inc.NCT01771848Written as PfSPZ Challenge
- Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune AdultsCompletedPhase 1Sanaria Inc.NCT01624961Written as PfSPZ Challenge
- Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ ChallengeCompletedPhase 1Sanaria Inc.NCT02237586Written as PfSPZ Challenge
- Experimental Human Malaria Infection by PfSPZCompletedPhase 1Sanaria Inc.NCT01086917Written as PfSPZ Challenge
- Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian AdultsCompletedPhase 1Sanaria Inc.NCT01540903Written as PfSPZ Challenge
Given in every arm · 3 — PfSPZ Challenge is usual care beside what is tested
- Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina FasoNot yet recruitingPhase 1Sanaria Inc.NCT07730177Written as PfSPZ Challenge
- Chemoprophylactic Activity of M5717 in PfSPZ Challenge ModelCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04250363Written as PfSPZ Challenge
- Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P ChemoprophylaxisCompletedPhase 1University Hospital TuebingenNCT02858817Written as PfSPZ Challenge (NF54)